Mili Shum
Allergy & Immunology · West Harrison, NYNPI 1407134224
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,255 of the $94,680 with a category attached, or 61.5%. GSK accounts for 77.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $46,945 and has fallen 90.8% since, to $4,307 in 2025. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $544.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$73K
- Pfizer$10K
- Novartis$6K
- AstraZeneca$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$324
- plus $2K from 14 others
Across 20 payments — averaging $41,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$734K
- GSK$95K
What the payments were for
- Consulting fees$27,92429%
- Speaking & faculty fees$58,25562%
- Travel & lodging$1,5422%
- Food & beverage$6,9557%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $73,086 |
| Pfizer | 18 | $10,458 |
| Novartis | 20 | $6,377 |
| AstraZeneca | 30 | $1,855 |
| Sanofi | 14 | $1,052 |
| Regeneron Healthcare Solutions, Inc. | 4 | $324 |
| ADMA Biomanufacturing LLC | 2 | $274 |
| Shire North American Group Inc | 7 | $245 |
| Regeneron | 3 | $207 |
| Biocryst US Sales Co., LLC | 2 | $187 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Blueprint Medicines Corporation | 2 | $121 |
| CSL Behring | 4 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $75 |
| Kaleo, Inc. | 3 | $69 |
| Genentech USA, Inc. | 2 | $34 |
| Grifols USA, LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $19 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,680 in reported general payments places this provider in the 90th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 19 | $109,700 |
| NucalaMepolizumab | 14 | $94,975 |
| XolairOmalizumab | 17 | $45,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $26,091 |
| Epinephrine | 83 | $18,847 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,562 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,775 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,179 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,617 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $3,427 |
| Fluticasone Propionate | 111 | $1,563 |
| Azelastine Hcl | 50 | $1,479 |
| Ipratropium Bromide | 18 | $859 |
| Montelukast Sodium | 101 | $704 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $73,086 | $132,62854 claims |
| AstraZenecaSymbicort | $1,855 | $5,17921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in West Harrison
- Ujwala KazaNew York$1.1M
- Syed MustafaRochester$948K
- Robert SporterNew York$946K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$643K
- Robert TamayevRego Park$321K
- Richard InselNew York$269K
- Payel GuptaBrooklyn$256K
- Luz FonacierMineola$237K
- Mark Davis-LortonTarrytown$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.